China Biologic Products Holdings, Inc. (CBPO): Price and Financial Metrics


China Biologic Products Holdings, Inc. (CBPO)

Today's Latest Price: $106.70 USD

6.70 (6.70%)

Updated Apr 8 6:55pm

Add CBPO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 117 in China

See all "A" rated Strong Buy stocks

CBPO Stock Summary

  • For CBPO, its debt to operating expenses ratio is greater than that reported by just 0.34% of US equities we're observing.
  • CBPO's price/sales ratio is 8.28; that's higher than the P/S ratio of 90.06% of US stocks.
  • The volatility of China Biologic Products Holdings Inc's share price is greater than that of merely 6.85% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to China Biologic Products Holdings Inc, a group of peers worth examining would be IMAX, ROLL, TTGT, TC, and MICT.
  • Visit CBPO's SEC page to see the company's official filings. To visit the company's web site, go to www.chinabiologic.com.
CBPO Daily Price Range
CBPO 52-Week Price Range

CBPO Stock Price Chart More Charts


CBPO Price/Volume Stats

Current price $106.70 52-week high $119.44
Prev. close $100.00 52-week low $88.00
Day low $99.13 Volume 287,100
Day high $106.99 Avg. volume 130,122
50-day MA $112.83 Dividend yield N/A
200-day MA $109.48 Market Cap 4.20B

China Biologic Products Holdings, Inc. (CBPO) Company Bio


China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.

CBPO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$106.70$146.2246%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for China Biologic Products Holdings Inc. To summarize, we found that China Biologic Products Holdings Inc ranked in the 51th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of China Biologic Products Holdings Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 300.33 -- which is good for besting 97.07% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 68.34% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%43%
1%45%
2%46%
3%48%
4%49%
5%51%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CBPO, try LH, UHS, HCSG, NVST, and DGX.


CBPO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CBPO Latest Social Stream


Loading social stream, please wait...

View Full CBPO Social Stream

CBPO Price Returns

1-mo -7.98%
3-mo -8.26%
6-mo -7.36%
1-year 10.49%
3-year 1.29%
5-year 10.19%
YTD -8.32%
2019 53.31%
2018 -3.63%
2017 -26.74%
2016 -24.53%
2015 111.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.936 seconds.